Johnson&Johnson considers HBV RNAi-related HBV efforts No. 1 2019 breakthrough | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34757 of 34789  at  1/28/2020 6:35:19 AM  by

Biogiek


Johnson&Johnson considers HBV RNAi-related HBV efforts No. 1 2019 breakthrough

The fact they selected HBV and refer to the HBV-RNAi centered REEF study as their No. 1 2019 'epic' breakthrough, speaks to the potentially tremdendous value of Arbutus' HBV RNAi program. If anybody knows about the real potential of RNAi for the HBV 'cure' goal (i.e. has full insights into clinical dataset), then it is JNJ.

This means that if Artubutus' RNAi candidate is fairly potent and safe, it will have a significant market value.

https://www.careers.jnj.com/careers/3-epic-health-breakthroughs-from-2019


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 219
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...